X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
Under the terms of the agreement, Be Bio obtains non-exclusive research, clinical and commercial rights to use MaxCyte’s Flow Electroporation® technology and ExPERT platform to support the development of Be Bio’s BCMs programs.
Lead Product(s): B Cell-based Therapy
Therapeutic Area: Genetic Disease Product Name: Undisclosed
Highest Development Status: PreclinicalProduct Type: Cell and Gene therapy
Recipient: MaxCyte
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement April 02, 2024
Details:
BE-101 is a novel engineered B cell medicine, which produces active and sustained levels of Factor IX (FIX) and it is currently being evaluated for the treatment of hemophilia B.
Lead Product(s): BE-101
Therapeutic Area: Genetic Disease Product Name: BE-101
Highest Development Status: PreclinicalProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 10, 2023
Details:
Proceeds will advance autologous and allogeneic Engineered B Cell Medicine (BeCM) platforms, as well as progress pipeline candidates in oncology and rare disease toward investigational new drug (IND) applications.
Lead Product(s): Engineered B Cell Medicine
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: UndisclosedProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: ARCH Venture Partners
Deal Size: $130.0 million Upfront Cash: Undisclosed
Deal Type: Series B Financing April 14, 2022
Details:
The company plans to use this funding to precisely engineer B cells to treat a range of diseases, building on the pioneering work of Drs. Rawlings and James at Seattle Children’s Research Institute.
Lead Product(s): Engineer B cells
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: UndisclosedProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Longwood Fund
Deal Size: $52.0 million Upfront Cash: Undisclosed
Deal Type: Series A Financing October 22, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
